Intestinal microbiota and Relapse after hematopoietic-Cell transplantation

Journal of Clinical Oncology

Volumn 35, Issue 15, 2017, Pages 1650-1659

  Peled, Jonathan U ^a,b   Devlin, Sean M ^a   Staffas, Anna ^a   Lumish, Melissa ^a,c   Khanin, Raya ^a   Littmann, Eric R ^a   Ling, Lilan ^a   Kosuri, Satyajit ^a   Maloy, Molly ^a   Slingerland, John B ^a   Ahr, Katya F ^a   Porosnicu Rodriguez, Kori A ^a   Shono, Yusuke ^a   Docampo, Melissa D ^a,b   Gyurkocza, Boglarka ^a,b   Sung, Anthony D ^d   Weber, Daniela ^e   Alousi, Amin M ^f   Giralt, Sergio A ^a,b   Taur, Ying ^a,b   Pamer, Eric G ^a,b   Jenq, Robert R ^a,b   Van Den Brink, Marcel R M ^a,b   more..

^a Memorial Sloan Kettering Cancer Center   (Canada)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^d DUKE UNIVERSITY   (United States)

^e UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^f UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RNA 16S; TUMOR MARKER;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE MYELOID LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER RECURRENCE; CLINICAL OUTCOME; EUBACTERIUM LIMOSUM; FEMALE; FOLLOW UP; HUMAN; INTESTINE FLORA; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; OBSERVATIONAL STUDY; PHYLOGENETIC TREE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; ADVERSE EFFECTS; ALLOTRANSPLANTATION; FECES; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; METABOLISM; MICROBIOLOGY; MIDDLE AGED; NEOPLASMS; PHYSIOLOGY;

BIOMARKERS, TUMOR; FECES; FEMALE; GASTROINTESTINAL MICROBIOME; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS;

EID: 85021854564     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.70.3348     Document Type: Article

References (43)

1. Gratwohl A, Baldomero H, Aljurf M, et al: Hematopoietic stem cell transplantation: A global perspective. JAMA 303:1617-1624, 2010
2. Gooley TA, Chien JW, Pergam SA, et al: Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 363:2091-2101, 2010
3. Anasetti C, Logan BR, Lee SJ, et al: Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med 367:1487-1496, 2012
4. Armand P, Kim HT, Logan BR, et al: Validation and refinement of the disease risk index for allogeneic stem cell transplantation. Blood 123:3664-3671, 2014
5. Brunet S, Labopin M, Esteve J, et al: Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: A retrospective analysis. J Clin Oncol 30:735-741, 2012
6. Walter RB, Gooley TA, Wood BL, et al: Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol 29:1190-1197, 2011
7. Aoudjhane M, Labopin M, Gorin NC, et al: Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: A retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 19:2304-2312, 2005
8. Brunstein CG, Gutman JA, Weisdorf DJ, et al: Allogeneic hematopoietic cell transplantation for hematologic malignancy: Relative risks and benefits of double umbilical cord blood. Blood 116:4693-4699, 2010
9. Milano F, Gooley T, Wood B, et al: Cord-blood transplantation in patients with minimal residual disease. N Engl J Med 375:944-953, 2016
10. Shaw BE, Gooley TA, Malkki M, et al: The importance of HLA-DPB1 in unrelated donor hematopoietic cell transplantation. Blood 110:4560-4566, 2007
11. Fleischhauer K, Shaw BE, Gooley T, et al: Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: A retrospective study. Lancet Oncol 13: 366-374, 2012
12. Venstrom JM, Pittari G, Gooley TA, et al: HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. N Engl J Med 367:805-816, 2012
13. Horowitz MM, Gale RP, Sondel PM, et al: Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75:555-562, 1990
14. Pavletic SZ, Kumar S, Mohty M, et al: NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: Report from the committee on the epidemiology and natural history of relapse following allogeneic cell transplantation. Biol Blood Marrow Transplant 16:871-890, 2010
15. Belkaid Y, Hand TW: Role of the microbiota in immunity and inflammation. Cell 157:121-141, 2014
16. Taur Y, Xavier JB, Lipuma L, et al: Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 55:905-914, 2012
17. Jenq RR, Ubeda C, Taur Y, et al: Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. J Exp Med 209: 903-911, 2012
18. Jenq RR, Taur Y, Devlin SM, et al: Intestinal blautia is associated with reduced death from graft-versus-host disease. Biol Blood Marrow Transplant 21:1373-1383, 2015
19. Holler E, Butzhammer P, Schmid K, et al: Metagenomic analysis of the stool microbiome in patients receiving allogeneic stem cell transplantation: Loss of diversity is associated with use of systemic antibiotics and more pronounced in gastrointestinal graft-versus-host disease. Biol Blood Marrow Transplant 20:640-645, 2014
20. Shono Y, Docampo MD, Peled JU, et al: Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice. Sci Transl Med 8:339ra71, 2016
21. Mathewson ND, Jenq R, Mathew AV, et al: Gut microbiome-derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease. Nat Immunol 17:505-513, 2016
22. Eriguchi Y, Takashima S, Oka H, et al: Graft-versus-host disease disrupts intestinal microbial ecology by inhibiting Paneth cell production of a--defensins. Blood 120:223-231, 2012
23. Harris B, Morjaria SM, Littmann ER, et al: Gut microbiota predict pulmonary infiltrates after allogeneic hematopoietic cell transplantation. Am J Respir Crit Care Med 194:450-463, 2016
24. Taur Y, Jenq RR, Perales M-A, et al: The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. Blood 124:1174-1182, 2014
25. Paulos CM, Wrzesinski C, Kaiser A, et al: Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J Clin Invest 117:2197-2204, 2007
26. Iida N, Dzutsev A, Stewart CA, et al: Com-mensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 342:967-970, 2013
27. Sivan A, Corrales L, Hubert N, et al: Com-mensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350: 1084-1089, 2015
28. Vétizou M, Pitt JM, Daillère R, et al: Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350:1079-1084, 2015
29. Viaud S, Saccheri F, Mignot G, et al: The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 342:971-976, 2013
30. Zitvogel L, Galluzzi L, Viaud S, et al: Cancer and the gut microbiota: An unexpected link. Sci Transl Med 7:271ps1, 2015
31. Daillère R, Vétizou M, Waldschmitt N, et al: Enterococcus hirae and Barnesiella intestinihominis facilitate cyclophosphamide-induced therapeutic immunomodulatory effects. Immunity 45:931-943, 2016
32. Holler E, Hahn J, Andreesen R, et al: NOD2/ CARD15 polymorphisms in allogeneic stem-cell transplantation from unrelated donors: T depletion matters. J Clin Oncol 26:338-339, author reply 339, 2008
33. Edgar RC: UPARSE: Highly accurate OTU sequences from microbial amplicon reads. Nat Methods 10:996-998, 2013
34. Mano A, Falcão A, Godinho I, et al: CA-125 AUC as a new prognostic factor for patients with ovarian cancer. Gynecol Oncol 97:529-534, 2005
35. Oudard S, Banu E, Thiounn N, et al: Corrected area under serum PSA curve as a predictor of survival after chemotherapy for hormone-refractory prostate cancer (HRPC) patients. J Clin Oncol 22:9579, 2004 (suppl; abstr 9579)
36. Wolbers M, Blanche P, Koller MT, et al: Concordance for prognostic models with competing risks. Biostatistics 15:526-539, 2014
37. Sorror ML, Storb RF, Sandmaier BM, et al: Comorbidity-age index: A clinical measure of biologic age before allogeneic hematopoietic cell transplantation. J Clin Oncol 32:3249-3256, 2014
38. Hooper LV, Littman DR, Macpherson AJ: Interactions between the microbiota and the immune system. Science 336:1268-1273, 2012
39. Rajilić-Stojanović M, de Vos WM: The first 1,000 cultured species of the human gastrointestinal microbiota. FEMS Microbiol Rev 38:996-1047, 2014
40. Kanauchi O, Fukuda M, Matsumoto Y, et al: Eubacterium limosum ameliorates experimental colitis and metabolite of microbe attenuates colonic inflammatory action with increase of mucosal integrity. World J Gastroenterol 12:1071-1077, 2006
41. Biagi E, Nylund L, Candela M, et al: Through ageing, and beyond: Gut microbiota and inflammatory status in seniors and centenarians. PLoS One 5:e10667, 2010
42. Yutin N, Galperin MY: A genomic update on clostridial phylogeny: Gram-negative spore formers and other misplaced clostridia. Environ Microbiol 15: 2631-2641, 2013
43. Peled JU, Jenq RR, Holler E, et al: Role of gut flora after bone marrow transplantation. Nat Microbiol 1:16036, 2016